Last reviewed 2026-04-23 · How we verify

TRC150094

TRC150094 is a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that enhances insulin sensitivity and lipid metabolism.

TRC150094 is a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that enhances insulin sensitivity and lipid metabolism. Used for Type 2 diabetes mellitus, Non-alcoholic fatty liver disease (NAFLD).

At a glance

Mechanism of action

PPARδ agonists activate the delta isoform of peroxisome proliferator-activated receptors, which regulate genes involved in fatty acid oxidation and glucose homeostasis. TRC150094 is designed to improve metabolic parameters in insulin-resistant conditions by promoting lipid utilization and reducing hepatic glucose production, with a favorable safety profile compared to earlier PPAR agonists.

Approved indications

• Type 2 diabetes mellitus
• Non-alcoholic fatty liver disease (NAFLD)

Common side effects

• Edema
• Weight gain
• Gastrointestinal disturbances

Key clinical trials

• Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension (PHASE3)
• Hyperinsulinemic Euglycemic Clamp Protocol (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• TRC150094 CI brief — competitive landscape report
• TRC150094 updates RSS · CI watch RSS
• Torrent Pharmaceuticals Limited portfolio CI